The Psychedelic Renaissance and How It Will Transform Health Care
summary
Claims that ibogaine for opioid addiction saves lives and that MDMA could win FDA approval soon are backed here by a family tragedy turned foundation and by funding for trials; asserted effect sizes range as high as 70–90% response rates for some indications, therapy sessions cost roughly $80k per course today, AI is proposed to personalize diagnostics and scale therapy, and regulators already permit ~8,000 treated patients in Oregon. Veterans and bipartisan politics drive access.
AI-written summary · about
chapters (9)
- 0:00Intro
- 2:52How did you get into this
- 4:18A new era of health care
- 6:38The future of psychedelics
- 9:46Biggest challenge to change the narrative
- 13:03How to deal with conservatives
- 14:11bipartisan approach
- 16:28AI
- 21:19Moonshot
related talks
21mThe Patient as CEO
25mThe Ethical Introduction of AI in Clinical Practice: Is There Such a Thing?
22mAI Powering New Health Solutions
40mDistributing Decision Support with FHIR
32mThe Parallels and Peculiarities of Selling Clinical AI Into Hospitals
24mLeveraging Voice in Healthcare After COVID
21mInvesting in Human Assisted Intelligence
10mIntelligent Health AI Conference September 2020 - Ampersand Health